TSS
SPRO icon

Two Sigma Securities’s Spero Therapeutics SPRO Stock Holding History

Two Sigma Securities’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-67,728
Closed -$88K – 3583
2024
Q2 		$88K Buy
+67,728
New +$102K ﹤0.01% 2502
2024
Q1 		– Sell
-10,301
Closed -$15.1K – 3605
2023
Q4 		$15.1K Buy
+10,301
New +$12.3K ﹤0.01% 2764
2023
Q1 		– Sell
-23,523
Closed -$40.7K – 3232
2022
Q4 		$40.7K Buy
+23,523
New +$43.9K ﹤0.01% 2190

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Two Sigma Securities's SPRO Position: Q3 2024 in Review

Two Sigma Securities sold out of Spero Therapeutics (SPRO) in Q3 2024, closing a stake of 67,728 shares — an estimated $88K sold.

Two Sigma Securities first reported a position in SPRO in Q4 2022 and held it in 3 quarters. The position peaked at $88K in Q2 2024. 46 funds tracked by Wall St. Rank hold SPRO as of Q3 2024.

  • Two Sigma Securities reported no remaining Spero Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Securities sold 67,728 Spero Therapeutics shares in Q3 2024, an estimated $88K.
  • Two Sigma Securities first reported a position in Spero Therapeutics in Q4 2022 and held it in 3 quarters.
  • Two Sigma Securities's Spero Therapeutics position peaked at $88K in Q2 2024.
  • 46 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2024.

Based on Two Sigma Securities's 13F filing for Q3 2024, filed 14 Nov 2024.